Literature DB >> 18092846

Recurrent chondrosarcoma of the right skull base in a patient with Maffucci syndrome.

Mark Abdelmalek1, Christine Stanko.   

Abstract

Maffucci syndrome is a rare, sporadic disease characterized by the development of multiple enchondromas and subcutaneous hemangiomas. Patients with Maffucci syndrome have a 23-37% risk of malignancy, with chondrosarcomas being the most common. Although the development of a chondrosarcoma in a patient with Maffucci syndrome may be expected, intracranial chondrosarcomas are rare. We present a patient with Maffucci syndrome who was diagnosed with an intracranial chondrosarcoma after presenting with hearing loss and vomiting. After three craniotomies and two recurrences of chondrosarcoma of the right skull base, the patient demonstrated a positive outcome to treatment with external radiation therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18092846     DOI: 10.2165/00128071-200809010-00008

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  4 in total

Review 1.  A case of Ollier disease with non-small cell lung cancer and review of the literature.

Authors:  Omer Faruk Sendur; Yasemin Turan; Bengu Beydag Odabasi; Isil Karatas Berkit
Journal:  Rheumatol Int       Date:  2009-06-06       Impact factor: 2.631

2.  The association between intracranial tumours and multiple dyschondroplasia (Ollier's disease or Maffucci's syndrome): do children and adults differ?

Authors:  Adrianna Ranger; Artur Szymczak
Journal:  J Neurooncol       Date:  2009-06-09       Impact factor: 4.130

3.  Intra-cranial Chondroma: A Case Report and Problematic Diagnosis.

Authors:  Arezoo Eftekhar Javadi; Elham Nazar; Hedieh Moradi Tabriz
Journal:  Iran J Pathol       Date:  2020-12-26

4.  Cell-free DNA from plasma as a promising alternative for detection of gene mutations in patients with Maffucci syndrome.

Authors:  Yi Sun; Xindong Fan; Yamin Rao; Zhenfeng Wang; Deming Wang; Xitao Yang; Lianzhou Zheng; Mingzhe Wen; Ren Cai; Lixin Su
Journal:  Hereditas       Date:  2022-01-18       Impact factor: 3.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.